P3 Research to move in with AusTrials

Genesis Capital's Dr Michael Caristo. (Image: Genesis Capital)

Tue, 01 Aug 2023

Healthcare private equity investor Genesis Capital has added clinical trials company AusTrials to its portfolio, with plans to wrap it up into a trans-Tasman offering with New Zealand's P3 Research.The Sydney firm bought a 90% stake in P3 in December and indicated investing $30 million to back P3's growth trials.P3 is the largest player in the NZ market for large- and small-scale early trial work, alongside Pacific Clinical Research Network and NZ Clinical Research.A 2020 report by the NZ Institute of Economic Research estimated clinica...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.